Enterprise Value
259M
Cash
21.25M
Avg Qtr Burn
-11.66M
Short % of Float
0.05%
Insider Ownership
0.05%
Institutional Own.
15.49%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Eblasakimab (ASLAN004) (IL-13Ra1 inhibitor) Details Atopic dermatitis | Phase 2b Update | |
Eblasakimab Details Atopic dermatitis | Phase 2 Data readout | |
Farudodstat (ASLAN003) (DHODH inhibitor) Details Autoimmune disease, Alopecia areata | Phase 2a Data readout |